Collegium Pharma (COLL) Stock Price, Quote & News

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 713 3699

Website: www.collegiumpharma.com

Address:

100 Technology Center Drive, Suite 300, Stoughton, United States

JR603 Nov. 12 at 10:14 PM

$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!

0 · Reply

Itinerant Nov. 7 at 9:55 PM

$COLL I understand that some investors fear the risk of the opiod litigation and its potential damage to the valuation of COLL. I have added $500 million of such cost into the balance sheet of COLL, and I want to tell you that such a liability is not of serious consequence to the overall valuation of COLL. The company is substantially under valued and can absorb such a settlement cost without difficulty. Of course, I do not really know what such a settlement might prove to be. I am just guessing a number. But you get the idea. Having said that, the market will likely over react to any such settlement, as the market almost always over reacts. JMO

0 · Reply

MarkNewtonCMT Nov. 7 at 9:45 PM

$COLL Collegium Pharma (Gen.Drugs) popped this week out of a tight Cup and Handle formed back in early 2024 and one to certainly keep an eye on going forward. This @marketsurge chart by @IBDinvestors is on William O Neill's screen (85 stocks) & given Healthcare's success lately, still looks technically attractive on this high volume breakout. @InvestorsBusinessDaily

0 · Reply

jewell69 Nov. 7 at 6:58 PM

$COLL sold yesterday 11/6 on great earns day 11/06/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 51 $40.05 $0.01 $2,042.54 up even more today, friday 11/7/25 1:54 pm est 42.31 +another 4.06% for the day

0 · Reply

JarvisFlow Nov. 7 at 3:51 PM

Truist Securities has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 45 → 48.

0 · Reply

JarvisFlow Nov. 7 at 11:41 AM

HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Action List Buy, target set at 44 → 46.

0 · Reply

d_risk Nov. 6 at 4:40 PM

$COLL - Collegium Pharmaceutical Inc. Common Stock - 10Q - Updated Risk Factors COLL’s latest 10-Q expands risk disclosures, highlighting increased concerns over debt, product commercialization, regulatory hurdles, IP litigation, manufacturing reliance, market acceptance, opioid litigation, competition, cybersecurity, AI, and stock volatility. #Pharmaceuticals #MarketVolatility #Cybersecurity #OpioidLitigation #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/COLL/10-Q/2025-11-06

0 · Reply

jewell69 Nov. 6 at 2:43 PM

$COLL trades since september, 2025 9/12 b 101 38.24 10/20 s 50 33.98 able to do a quickie here 10/20 again b 50 33.61 cheaper than 33.98 sale earlier in the day. 10/20 AGAIN S 50 34.11. Now I am resigned to just getting out of half of it at an overall loss s 51 today 11/6 40.05 net net 106.24 loss

0 · Reply

jewell69 Nov. 6 at 1:58 PM

$COLL got painkillers ? - Earnings Flash (COLL) Collegium Pharmaceutical Posts Q3 Adjusted EPS $2.25, vs. FactSet Est of $1.86 stock is up in pre-market.

0 · Reply

Stefan100 Nov. 6 at 1:10 PM

$COLL the company is continuing to execute and upped its guidance https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-third-quarter-2025-financial-results-raises

1 · Reply

Collegium to Participate in Upcoming Investor Conferences

Nov 10, 2025, 4:27 PM EST - 4 days ago

Collegium Pharmaceutical: Another Solid Quarter

Nov 6, 2025, 10:06 PM EST - 7 days ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 8 days ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Oct 30, 2025, 5:15 PM EDT - 15 days ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Oct 23, 2025, 8:00 AM EDT - 22 days ago

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 8:00 AM EDT - 23 days ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Sep 8, 2025, 5:03 PM EDT - 2 months ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 7, 2025, 2:00 PM EDT - 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 8:00 AM EDT - 4 months ago

Collegium Announces $150 Million Share Repurchase Program

Jun 30, 2025, 2:53 PM EDT - 4 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

May 12, 2025, 8:05 AM EDT - 6 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 9, 2025, 2:04 AM EDT - 6 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 6 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 8 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 8 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 10, 2025, 6:57 PM EDT - 8 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 9, 2025, 4:07 AM EDT - 8 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Feb 27, 2025, 9:03 PM EST - 9 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 9 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 8:00 AM EST - 9 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Jan 8, 2025, 8:00 AM EST - 11 months ago

Collegium Provides 2025 Financial Guidance and Business Update

Nov 26, 2024, 8:00 AM EST - 1 year ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Feb 22, 2024, 9:52 PM EST - 1 year ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:09 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 8, 2024, 8:00 AM EST - 1 year ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Nov 27, 2023, 8:00 AM EST - 2 years ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 7, 2023, 10:15 PM EST - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 2 years ago

Collegium Reports Third Quarter 2023 Financial Results

Oct 24, 2023, 2:59 PM EDT - 2 years ago

Collegium Pharmaceutical: Delivering On Promises

JR603 Nov. 12 at 10:14 PM

$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!

0 · Reply

Itinerant Nov. 7 at 9:55 PM

0 · Reply

MarkNewtonCMT Nov. 7 at 9:45 PM

0 · Reply

jewell69 Nov. 7 at 6:58 PM

0 · Reply

JarvisFlow Nov. 7 at 3:51 PM

Truist Securities has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 45 → 48.

0 · Reply

JarvisFlow Nov. 7 at 11:41 AM

HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Action List Buy, target set at 44 → 46.

0 · Reply

d_risk Nov. 6 at 4:40 PM

0 · Reply

jewell69 Nov. 6 at 2:43 PM

0 · Reply

jewell69 Nov. 6 at 1:58 PM

$COLL got painkillers ? - Earnings Flash (COLL) Collegium Pharmaceutical Posts Q3 Adjusted EPS $2.25, vs. FactSet Est of $1.86 stock is up in pre-market.

0 · Reply

Stefan100 Nov. 6 at 1:10 PM

$COLL the company is continuing to execute and upped its guidance https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-third-quarter-2025-financial-results-raises

1 · Reply

Doozio Nov. 6 at 12:50 PM

$COLL or this morning as da huckleberries are thru da $$$$ during 🐒🍌🧠⏰♾️

0 · Reply

Doozio Nov. 5 at 7:48 PM

$COLL eps 2nte? 🐒🍌🧠⏰♾️

0 · Reply

WilkinsRF Oct. 20 at 9:53 PM

$COLL right near 35 from under 31. With this momentum we could be at new highs from earnings or before

0 · Reply

WilkinsRF Oct. 15 at 9:11 PM

$COLL reversal of flush out in progress. 35 to 40 could come fast

0 · Reply

WilkinsRF Oct. 9 at 4:03 PM

$COLL there is a group selling out but this will be a great buying opportunity. Keep accumulating. Reminds me of $HCI when it dropped below 100. Now it's 190. This is worth 60 easily

0 · Reply

WilkinsRF Oct. 6 at 8:54 PM

$COLL added today on recent weakness. Best adhd product on the market and should experience major multi year growth while enjoying high fcf from pain franchise

1 · Reply

jewell69 Oct. 3 at 6:20 PM

TRYING 2 BY 90 $DKNG 35.10 now b a .21 x .22 moved from Greece $GREK to Chile $ECH TOOK 1.4% PROFIT IN $COLL B YESTERDAY, 10/2 SOLD TODAY 10/3

0 · Reply

jewell69 Oct. 3 at 6:00 PM

$COLL B 10/2 34.30 S TODAY 10/3 34.66

0 · Reply

hawkmdend Oct. 3 at 3:43 PM

$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.

1 · Reply

jewell69 Oct. 2 at 5:10 PM

$COLL trying 2 by 200 34.30 now 1:04 pm edt b a 34.39 x .42 recent historical trades: 09/19/2025 Sell COLLEGIUM PHARMACEUTICAL 100 $35.8159 $0.02 $3,581.57 09/15/2025 Buy COLLEGIUM PHARMACEUTICAL 100 $34.92 -$3,492.00 09/11/2025 Sell COLLEGIUM PHARMACEUTICAL 100 $38.5246 $0.02 $3,852.44 09/08/2025 Buy COLLEGIUM PHARMACEUTICAL 50 $37.58 -$1,879.00 09/08/2025 Buy COLLEGIUM PHARMACEUTICAL 50 $38.09 -$1,904.50 05/23/2025 Sell COLLEGIUM PHARMACEUTICAL 22 $27.06 $595.32 05/20/2025 Buy COLL GIUM PHARMECEUTICAL 22 $30.11 -$662.42 05/20/2025 Sell

0 · Reply

TalkMarkets Sep. 27 at 3:20 AM

Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI $MASI $COLL Also $ALC $SONVY https://talkmarkets.com/content/stocks--equities/dont-overlook-these-2-highly-ranked-medical-stocks-coll-masi?post=525107

0 · Reply

AnneLee847 Sep. 21 at 5:55 AM

$COLL Cosmetic dermatology play. Testing multi-month support. Volume decline concerning.

0 · Reply

Market Cap	1.50B
Revenue (ttm)	631.45M
Net Income (ttm)	69.19M
EPS (ttm)	N/A
PE Ratio	7.02
Forward PE	7.15
Profit Margin	10.96%
Debt to Equity Ratio	2.07

Volume	339,049
Avg Vol	449,710
Day's Range	N/A - N/A
Shares Out	31.61M
Stochastic %K	86%
Beta	0.61
Analysts	Strong Sell
Price Target	$46.40